Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018
Radioimmunolocalization of an /sup 111/In-labeled mouse antimelanoma monoclonal antibody (MoAb), ZME-018, was examined in 21 patients with metastatic malignant melanoma. Each patient received a single. i.v. infusion of MoAb at concentrations ranging from 1 mg to 20 mg, coupled to 5 mCi /sup 111/In by the chelating agent DPTA. No toxicity was observed in any patient. Total-body and regions of interest scans performed at 4, 24, and 72 hr following MoAb administration revealed uptake in 63 out of 105 previously diagnosed metastases for an overall sensitivity of 60%. Uptake was consistently observed in liver/spleen, and less frequently in bowel, testes, axillae and bone. Sensitivity of detection increased significantly at doses of MoAb above 2.5 mg, with 74% of lesions imaging at 20 mg/5 mCi compared with 29% at 2.5 mg/5 mCi (p less than 0.005). A significant correlation was observed between tumor uptake of /sup 111/In-MoAb conjugate and increasing tumor size. Soft-tissue lesions such as skin and lymph node metastases were imaged to a greater extent (76%) than visceral metastases (19%). In five of six patients, biopsies obtained from 3 days to 14 days after MoAb administration showed antibody present on tumor cells as demonstrated by flow cytometry and/or radioimmunoassay. Human anti-murine immunoglobulin responses were observed in seven of 17 patients studied. Mean plasma clearance of ZME-018 was prolonged with a T1/2 of 24.7 hr and increased slightly with increasing MoAb dose. Urinary excretion of /sup 111/In averaged 12.4% of the injected dose over 48 hours. Radioimmunolocalization of melanoma with /sup 111/In-labeled ZME-018 appears feasible. The sensitivity of the technique was related to dose, tumor size, and disease site.
- OSTI ID:
- 6929103
- Journal Information:
- J. Nucl. Med.; (United States), Vol. 1
- Country of Publication:
- United States
- Language:
- English
Similar Records
Imaging findings and pharmacokinetics of 111-indium ZME-018 monoclonal antibody (MoAb) in malignant melanoma
Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018)
Related Subjects
62 RADIOLOGY AND NUCLEAR MEDICINE
INDIUM 111
UPTAKE
MELANOMAS
DIAGNOSIS
MONOCLONAL ANTIBODIES
BIOLOGICAL LOCALIZATION
ANTIBODY FORMATION
BLOOD-PLASMA CLEARANCE
CELL FLOW SYSTEMS
DTPA
LARGE INTESTINE
LIVER
LYMPH NODES
METASTASES
PATIENTS
RADIOIMMUNOASSAY
RADIOIMMUNOLOGY
RADIOISOTOPE SCANNING
SKELETON
SKIN
SPLEEN
TESTES
TISSUE DISTRIBUTION
AMINO ACIDS
ANTIBODIES
BETA DECAY RADIOISOTOPES
BODY
CARBOXYLIC ACIDS
CHELATING AGENTS
CLEARANCE
COUNTING TECHNIQUES
DAYS LIVING RADIOISOTOPES
DIGESTIVE SYSTEM
DISEASES
DISTRIBUTION
DRUGS
ELECTRON CAPTURE RADIOISOTOPES
GASTROINTESTINAL TRACT
GLANDS
GONADS
IMMUNOASSAY
IMMUNOLOGY
INDIUM ISOTOPES
INTERMEDIATE MASS NUCLEI
INTESTINES
ISOMERIC TRANSITION ISOTOPES
ISOTOPE APPLICATIONS
ISOTOPES
LYMPHATIC SYSTEM
MALE GENITALS
MINUTES LIVING RADIOISOTOPES
NEOPLASMS
NUCLEI
ODD-EVEN NUCLEI
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANS
RADIOASSAY
RADIOISOTOPES
RADIOPROTECTIVE SUBSTANCES
TRACER TECHNIQUES
550901* - Pathology- Tracer Techniques
550601 - Medicine- Unsealed Radionuclides in Diagnostics